Crohn’s disease: NOD2, autophagy and ER stress converge

Teresa Fritz, Lukas Niederreiter, Timon Adolph, Richard S Blumberg, Arthur Kaser

ABSTRACT
Polymorphisms in NOD2, encoding an intracellular pattern recognition receptor, contribute the largest fraction of genetic risk for Crohn’s disease among the >40 risk loci identified so far. Autophagy plays a prominent role in the innate immune response towards intracellular bacteria. The discovery of the autophagy genes ATG16L1 and IRGM as risk factors for Crohn’s disease turned autophagy into the spotlight in inflammatory bowel disease (IBD). Remarkably, NOD2 has recently been identified as a potent autophagy inducer. A physical interaction of NOD2 and ATG16L1 appears to be required for autophagic clearance of intracellular pathogens. Moreover, Crohn’s disease-associated NOD2 and ATG16L1 variants exhibit a defect in the induction of an autophagic response and hence predict autophagy as a key converging mechanism that leads to Crohn’s disease. Another pathway that is closely intertwined with autophagy and mutually cross-regulated is the unfolded protein response (UPR), which is induced by endoplasmic reticulum (ER) stress. Genes involved in the UPR (XBP1, ORMDL3) have also been genetically associated with Crohn’s disease and ulcerative colitis. Moreover, the intestinal epithelium at the interface between host and microbiota appears particularly affected by IBD-associated hypomorphic function of autophagy and the UPR. The functional convergence of main genetic risk factors for IBD on these innate immune pathways has hence important implications for the host’s interaction with the microbiota. Moreover, the genetic convergence on these molecular mechanisms may open novel therapeutic options for IBD that deserve further exploration.

INTRODUCTION
Crohn’s disease and ulcerative colitis, the main clinical phenotypes of inflammatory bowel disease (IBD), are complex diseases arising from the interplay of genes that regulate immune function within the environment. Both diseases exhibit a particularly complex genetic underpinning, and share ~50–40% of the genetic risk loci, despite their phenotypic differences in presentation. Apart from the divergent role of smoking in Crohn’s disease and ulcerative colitis, little is known about environmental factors influencing IBD pathogenesis. Concordance rates in twin studies suggest a larger environmental contribution in ulcerative colitis compared to Crohn’s disease.

The discovery of an association between polymorphisms in NOD2 and Crohn’s disease in 2001 (table 1) represented one of the great advances in our understanding of polygenic diseases in general, with important implications beyond IBD. It provided the proof that functional variants of single genes could indeed be identified in a polygenic disease. Due to the advent of high-throughput genotyping strategies, genome-wide association studies (GWAS) became possible and have yielded a dramatic expansion of our insight into the genetic basis of IBD over the last few years, with now ~50 loci associated with both forms of IBD, Crohn’s disease and ulcerative colitis. NOD2 was also a ‘bonanza’ in that the genetic variants most strongly associated with Crohn’s disease were located in the coding region and led to an altered amino acid sequence, either due to an insertion that resulted in a frame-shift mutation, or through non-synonymous SNPs that resulted in amino acid exchanges (table 1). Crohn’s disease-associated genetic variants were all located in the so-called leucine-rich repeat (LRR) region of NOD2, the ligand-binding domain of this intracellular pattern recognition receptor and hence suggested a common functional theme in the relationship between NOD2 and Crohn’s disease pathogenesis. Since then, apart from the variants commonly observed in Crohn’s disease (termed SNP8 (R702W), SNP12 (G908R), and SNP13 (1007fs) in the initial publication; table 1), a number of rare NOD2 variants have been discovered that add to the genetic association of this locus to Crohn’s disease, and again almost exclusively localise to the LRR region. This deep insight into the ‘functional’ genetic variants of NOD2 contrasts significantly with the level of functional—genetic insights available to date for almost all of the other novel loci discovered through GWAS. While the locus associations based on surveying a limited number (currently 500–1000k) of SNPs are firmly established and reproducible, in many cases these loci harbour multiple genes that appear equally likely as potential causative candidates from a purely genetic point of view. Since DNA is inherited in larger chunks of 50–100 kb (haplotypes) across generations, current GWAS technology does not always allow the resolution of associated loci to individual genes or further to causal variants within these genes. Moreover, in most instances, the causal variants at a specific locus remain unknown even despite substantial re-sequencing efforts (see below). Another major distinction of the NOD2 association from other genetic Crohn’s disease (or ulcerative colitis) associations is that its effect size

1580 Gut 2011;60:1580—1588. doi:10.1136/gut.2009.206466

Correspondence to
Dr Arthur Kaser, Department of Medicine II, (Gastroenterology & Hepatology), Anichstr 35, A-6020 Innsbruck, Austria; arthur.kaser@i-med.ac.at

Published Online First
19 January 2011

1Department of Medicine II (Gastroenterology & Hepatology), Innsbruck Medical University, Innsbruck, Austria
2Division of Gastroenterology, Hepatology and Endoscopy, Dept of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Recent advances in basic science

EDITOR’S CHOICE

1580 Gut 2011;60:1580—1588. doi:10.1136/gut.2009.206466
Table 1  Summary of genetic variants mentioned in the text

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Common name</th>
<th>Nucleotide variant</th>
<th>Protein coding variant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOD2</td>
<td>rs2066844</td>
<td>SNP8</td>
<td>C2104T</td>
<td>R702W</td>
</tr>
<tr>
<td>NOD2</td>
<td>rs2066845</td>
<td>SNP12</td>
<td>G2722C</td>
<td>G908R</td>
</tr>
<tr>
<td>NOD2</td>
<td>rs2066847</td>
<td>SNP13</td>
<td>3020insC*</td>
<td>1007fs</td>
</tr>
<tr>
<td>ATG16L1</td>
<td>rs2241880</td>
<td></td>
<td>T→C</td>
<td>T300A</td>
</tr>
<tr>
<td>IRGM</td>
<td>rs13361189</td>
<td></td>
<td>in 5′ UTR †</td>
<td></td>
</tr>
<tr>
<td>XBP1</td>
<td>Multiple</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORMDL3</td>
<td>rs2872507</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*2939insC in mice.
† In perfect linkage disequilibrium with 20 kb deletion polymorphism in IRGM promoter.

is substantial, reflected in the fact that NOD2 variants alone account for the vast majority of the ~20% of heritability explained by all genetic loci associated with Crohn’s disease thus far.6

BIOLGORY OF NOD2

Despite the strong association between Crohn’s disease and causative NOD2 variants, a comprehensive picture of how NOD2 contributes to disease pathogenesis has not yet emerged (figure 1).13 NOD2 is broadly expressed intracellularly in macrophages, dendritic cells, and at lower levels in intestinal epithelial cells,12 and even in T cells.15 NOD2 is activated by N-acetyl muramyl dipeptide (MDP), a component of bacterial peptidoglycan.14 15 Additional ligands of NOD2 are N-glycolyl muramyl dipeptide from mycobacteria,16 and viral ssRNA.17 NOD2 activated by MDP binds to receptor-interacting serine/threonine kinase 2 (RIP2, RIPK2), which results in TRAF6-mediated ubiquitination of NF-κB essential modulator (NEMO, IKKγ) and hence activation of the NF-κB pathway.1 Activation of NOD2 through ssRNA activates an alternative pathway, triggering interferon-regulatory factor 3 (IRFs) activation through the adapter protein MAVS (mitochondrial antiviral signalling protein) and consequently production of interferon-β (IFNβ).17 The common Crohn’s disease-associated NOD2 variants abrogate RIP2 binding and consequently decrease NF-κB activation upon MDP stimulation.18 NOD2 is also involved in the modulation of Toll-like receptor (TLR) signalling.19 20 Specifically, Crohn’s disease-associated NOD2 variants may be inhibitory with regard to TLR2-induced NF-κB activation,15 especially upon chronic stimulation.21 While these data support a hypomorphic function of Crohn’s disease-associated NOD2 variants, the frame-shift NOD22920insC variant (SNP 15) has been suggested to encode a gain-of-function aspect by actively suppressing IL10 transcription via inhibiting the nuclear ribonucleoprotein hnRNP-A1.22 Furthermore, Nod2−/− mice exhibit decreased expression of specific antimicrobial α-defensins in Paneth cells. Along these lines, oral infection with Listeria monocytogenes led to increased translocation of this model pathogen to the liver and spleen in Nod2−/− mice.23 Similarly, patients with Crohn’s disease-associated NOD2 variants expressed decreased levels of α-defensins HD5 and HD6.24 Remarkably, neither Nod2−/− mice, nor mice engineered to express the murine homologue of the human NOD22920insC variant (ie, Nod22539insC) instead of wild-type Nod2 develop spontaneous intestinal inflammation under specific pathogen-free (SPF) conditions.25 26 Nod22539insC, but not Nod2−/− mice, exhibited increased severity in the dextran sodium sulfate (DSS)-induced colitis model.25 The Nod22539insC model was characterised by increased interleukin 1 β (IL-1β) release from MDP-stimulated macrophages, and blockade of IL-1β signalling alleviated the exaggerated DSS-induced colitis.25

AUTOPHAGY: A NOVEL PATHWAY EMERGES IN CROHN’S DISEASE

A fundamental cellular pathway that was until quite recently unexplored in IBD is autophagy.26 The discovery of a functional ATG16L1 polymorphism associated with Crohn’s disease initially reported by Schreiber and colleagues27 and later independently reported by other groups28 29 brought
Autophagy is an evolutionarily conserved self-cannibalistic catabolic lysosomal degradation pathway. Basal levels of autophagy occur in essentially all cells as a homeostatic function in the process of protein and organelle turnover. Autophagy is substantially upregulated when structural and transcriptional alterations in Paneth cells as did Atg16l1−/− mice held under conventional SPF conditions (ie, MNV infected). While there is no data yet that would support the suggestion that Crohn’s disease is a consequence of a MNV infection, the article by Cadwell et al provides an intriguing framework for gene–environment interactions.

In addition to these alterations in Paneth cells, LFS stimulation of myeloid cells deficient in ATG16L1 overactivates the inflammasome. This leads to IL-1β and IL-18 release through TRIF (Toll/IL-1 receptor domain-containing adaptor inducing IFNβ)-dependent activation of caspase-1. Despite these profound alterations in innate immune pathways, spontaneous intestinal inflammation was not observed in MNV-infected or non-infected Atg16l1−/− mice, or myeloid-specific Atg16l1−/− mice. However, MNV-infected, but not uninfected Atg16l1−/− mice exhibited increased susceptibility to DSS colitis, which could be abrogated by antibiotic treatment, or administration of anti-TNF or anti-IFNγ antibodies. Similarly, myeloid-specific Atg16l1−/− mice (with unknown MNV status) were more susceptible to DSS colitis than wild-type mice, which in this case was alleviated by IL-1β and IL-18 blockade.

**NOD2 REGULATES AUTOPHAGY**

Remarkably, two intriguing recent papers reported that NOD2 directly intersects with autophagy, and NOD2 might even physically interact with ATG16L1. Autophagy hence appears to be the key converging theme of two of the strongest genetic risk factors of Crohn’s disease (figure 5). Activation of NOD2 by bacterial ligands (MDP) and living bacteria leads to ATG16L1-dependent formation of autophagic vacuoles in dendritic cells and epithelial cells. Crohn’s disease-associated NOD2 variants lack this activity, and MDP-induced autophagy induction is also absent in cells harbouring the Crohn’s disease-associated ATG16L1 risk-conferring variant. A NOD2-dependent defect in bacteria-induced autophagy induction and its consequences on intracellular bacterial killing was demonstrated for Salmonella typhimurium, enterohaemorrhagic invasive Escherichia coli (AIEC; known to be intimately associated with epithelial cells in Crohn’s disease mucosa), as well as *Shigella flexneri*. Such a NOD2-related defect in autophagic removal of intracellular bacteria could be overcome by pharmacological...
Induction of autophagy with rapamycin. Mechanistically, it appears that normal NOD2, but not Crohn’s disease-associated NOD2 variants, recruits ATG16L1 to the plasma membrane at the bacterial entry site, and therefore NOD2 is critical for wrapping invading bacteria by autophagosomes. In addition to NOD2-induced autophagic innate immune response towards invading bacteria, NOD2-dependent autophagy in dendritic cells was also required for efficient antigen presentation and consequent induction of CD4+ T cell-dependent immunity towards a bacterial antigen. These studies extend the spectrum of bacterial pattern recognition receptors that may induce autophagy from various TLRs (TLR2, TLR3, TLR4, TLR7, TLR8; expressed on the cell surface or in endosomes) to the intracellular pattern recognition receptor NOD2 (as well as NOD1).

**ENDOPLASMIC RETICULUM STRESS**

Another pathway that has also recently emerged in IBD pathophysiology is the unfolded protein response (UPR), which is induced by endoplasmic reticulum (ER) stress. ER stress occurs upon the accumulation of misfolded or unfolded proteins in the ER, which initiates the UPR. The UPR is orchestrated by three major pathways and their associated transcription factors: PERK-ATF4, ATF6p90-ATF6p50 and IRE1-XBP1 (figure 4). ER stress has been genetically associated with both forms of IBD (Crohn’s disease and ulcerative colitis) through a candidate gene study of XBP1, as well as more recently through the GWAS-based identification of the ORMDL3 locus. The candidate-gene study of XBP1 was prompted by a mouse model with a partial or complete genetic deletion of Xbp-1 specifically in the intestinal epithelium. These mice developed spontaneous small intestinal inflammation with crypt abscesses, neutrophil infiltration, and ulcerations under SPF conditions, and hence closely mimicked the histological features of human IBD. Xbp-1 deletion in the epithelium resulted in substantial ER stress in the intestinal epithelial cell (IEC) compartment, and a marked pro-inflammatory hyper-reactivity of IECs towards microbial and cytokine stimuli. Decreased and absent XBP1 function in IECs resulted in Paneth cell dysfunction and their apoptotic depletion, respectively, with consequent impaired handling of model bacteria. A deep sequencing effort in >1000 patients and controls aimed at identifying potentially rare causal variants and indeed discovered 3-fold more rare single nucleotide polymorphisms (SNPs) in patients with IBD compared to healthy controls. Functional studies on rare non-synonymous SNPs (ie, SNPs that lead to an amino acid exchange; nsSNPs) revealed that IBD-only XBP1 nsSNP variants exhibited hypomorphic UPR induction, which was consistent with predictions from the mouse model.

The second ER stress-related IBD risk gene product, ORMDL3, localises to the ER membrane, and appears to be involved in protein folding and in regulating the extent of UPR activation. Functional ORMDL3 variants associated with IBD have not yet been identified and hence their biological effect on the UPR remains to be studied. Remarkably, there appears to be a very old phylogenetic link between innate immunity and the IRE1/XBP1 axis and the UPR in general. An intriguing study recently revealed that the xbp-1 pathway in *Caenorhabditis elegans* is required for the survival of the stress associated with an innate immune response towards a microbial infection. Along similar lines, TLR3 or TLR4 ligation on macrophages directly engages a UPR-related mechanism that allows inflammatory cells to survive the stress associated with their activated state. Moreover, only the intestinal epithelium expresses an additional isoform of IRE1 (termed IRE1β), the XBP1-activating endoribonuclease, in addition to ubiquitously expressed IRE1α; hence another phylogenetic hint on the importance of this pathway at the interface with the intestinal microbiome. TLR signalling might not only protect cells...
from ER stress, but may directly activate the IRE1α/XBP1 axis, which in turn is required for optimal pro-inflammatory cytokine secretion by macrophages and hence for the control of infections. It is not currently known whether NOD2 may activate IRE1α/XBP1 in a similar way as TLR ligation does.

Altogether, these studies indicate that the unfolded protein response and autophagy are deeply involved in innate immune mechanisms. This appears particularly relevant for host–microbiota interactions at the epithelial surface of the intestine in the context of IBD.

**INTER-RELATIONSHIP OF AUTOPHAGY AND ER STRESS**

The unfolded protein response and autophagy are also directly intimately intertwined (figure 5). ER stress per se is capable of activating autophagy, a function that is conserved from yeast to mammals. Specifically, c-Jun N-terminal kinase (JNK; overactivated in the context of hypomorphic XBP1) downstream of IRE1, and eukaryotic initiation factor 2α (eIF2α) downstream of PERK induce autophagosome formation under conditions of ER stress. Autophagy thereby complements ER-associated degradation (ERAD) induced during the UPR. Moreover, Chop and ATF4 downstream of PERK increase the transcription of essential autophagy genes. Another direct link from ER stress to autophagy induction is via Ca2+ release from the ER, which activates 5′-AMP-activated protein kinase (AMPK), and protein kinase C0 (PKC0), both potent inducers of autophagy.

Not only may ER stress induce autophagy, but vice versa, impaired autophagy can also promote ER stress. Specifically, suppression of a major protein involved in autophagosome formation, ATG7, in the liver leads to increased ER stress (with its downstream consequences), while restoration of ATG7 expression dampens ER stress. Hence, autophagy appears to be an important regulator of organelle—that is ER—function.

Further complicating the mechanistic understanding of the interaction between the UPR and autophagy is that key regulatory components of the class I phospho-inositol-5 kinase (PI3K), p85α and p85β, are involved in activation and nuclear shuttling of XBP1s. At the same time, class I PI3K proteins link receptor tyrosine kinases such as insulin-like or other growth factors to TOR activation and thereby repress autophagy. Additional central evidence for the close relationship between autophagy and the UPR comes from the fact that loss of tuberous sclerosis complex genes (TSC1 and TSC2), which leads to constitutive activation of mTOR, also leads to ER stress and activation of the UPR.

IECs appear particularly affected by aberrant autophagic function and impaired UPR signalling as observed in IBD. Both the UPR as well as autophagic responses are profoundly regulated in a cell-type and condition-specific way. Studies are currently under way to experimentally investigate the interplay between these disease pathways specifically in IECs. A recent paper on a model of amyotrophic lateral sclerosis (ALS), studying motor neurons in vivo, has provided intriguing insight into the functional interplay of a defective ER stress response and autophagy. Genetic deletion of Xbp1 was—contrary to expectations based on the massive induction of ER stress in ALS motorneurons—associated with amelioration of disease. This amelioration remarkably resulted from compensatory induction of autophagy secondary to Xbp1 deletion in the nervous system, which led to reduced accumulation of mutant protein aggregates. Hence, while it is clear that autophagy and ER stress may intersect at multiple layers, the exact nature of this interaction in IECs (and presumably also myeloid cells like macrophages) and its consequences for the development of IBD remains to be modelled in appropriate experimental systems.

**CLINICAL IMPLICATIONS**

As outlined above, impaired sensing and handling of (intracellular) bacteria by innate immune cells, in particular IECs, is a central theme in Crohn’s disease and related to the interconnected autophagic/UPR pathways. This might have several important implications with regard to the pathogenesis as well as the therapy of this form of IBD.

**Impaired handling of the microbiota**

Impaired bacterial-induced autophagy as a common theme in Crohn’s disease implies that a sizeable proportion of patients with Crohn’s disease may harbour a defect in handling of the intestinal microbiota by the host. Some characteristic alterations in the microbial composition at the immediate IEC interface have been described in patients with Crohn’s disease. High concentrations of bacteria were found attached to the mucosa in Crohn’s disease, and those patients with the highest bacterial concentrations had inclusions within individual IECs. Moreover, specific strains...
Figure 5 Relationship between endoplasmic reticulum (ER) stress and autophagy. Hypomorphic XBP1 function leads to ER stress and consecutive massive activation of inositol requiring enzyme-1 (IRE1), the kinase endo-ribonuclease upstream of XBP1, along with activation of other branches of the unfolded protein response (UPR). PERK activates elf2/ and hence halts protein translation, but can also induce autophagy. JNK is phosphorylated due to overactivated IRE1 involving the adaptor TRAF2, which in turn may induce autophagy, but also apoptosis if unrestrained. Furthermore, ER stress induction per se due to hypomorphic XBP1 function may lead to autophagy induction as a compensatory mechanism.

Potential future treatment options

The convergence of major genetic risk factors on autophagy and the inter-related UPR might offer novel avenues to therapeutic intervention. A preeminent key proximal regulator of autophagy is the target of rapamycin, mTOR kinase, which provides the major inhibitory signal that shuts off autophagy, when growth factors and nutrients are abundantly present. Pharmacological inhibition of mTOR with specific inhibitors like rapamycin or everolimus releases this inhibitory signal and induces activation of multiple ATG proteins that result in autophagosome formation. Indeed, rapamycin (sirolimus) treatment in a patient with Crohn’s disease who had failed steroid-sparing treatments such as azathio- prine, methotrexate and infliximab, has recently been reported in an instructive case report. Extending the novel genetic insight on the contribution of ‘hypomorphic’ autophagy to Crohn’s disease pathogenesis, rapamycin was administered for 6 months in a dose that yielded serum levels above 5 ng/ml. This was associated with marked clinical and endoscopic improvement. Of note, despite prior failure on infliximab, infliximab was continued during rapamycin therapy on scheduled intervals. Rapamycin is approved for clinical use in conjunction with other immunosuppressive medications in solid transplant recipients to avoid graft rejection but has also been used in preclinical studies for induction of autophagy in a model of Huntington’s disease. While a double-blind placebo-controlled clinical trial with rapamycin has not yet been performed, results of a trial with everolimus, another mTOR inhibitor, have recently been published. Specifically, this study was designed to compare everolimus with azathioprine and placebo to maintain steroid-induced remission, but was terminated early after a negative interim analysis. There was no difference between the three treatment arms, hence this study could not only alter the composition of the microbiota, but may also impart improperly towards the microbiota. In the case of hypomorphic XBP1, NOD2 and ATG16L1 function, IECs and macrophages may become hypersensitive to the products of the bacteria making the process of bacterial mishandling self-replicating. The convergence of the main Crohn’s disease-associated genetic risk factors on autophagy could also suggest that the host might be particularly at risk for bacteria that gain access to the cytoplasm of cells such as Mycobacteria sp., Shigella sp., Salmonella sp. or AIEC. Thus, these risk genes could render the host particularly susceptible to enteropathogens or pathobionts that require normal autophagic function for their eradication.

of E coli, namely adherent-invasive E coli (AIEC), may colonise the intestinal epithelial layer. AIEC are distinguishable from conventional commensal E coli in that they may adhere, invade and replicate within IECs. Notably, recent in vitro studies indicate that a subpopulation of AIEC resides within autophagosomes, and IRGM- and ATG16L1-deficient cells exhibit increased replication of AIEC. Moreover, DCs from patients with Crohn’s disease-associated NOD2 variants exhibited impaired intracellular bacterial killing, presumably due to a decrease of AIEC localisation to autophagolysosomes, which was reversible with the autophagy activator rapamycin. In addition to these effects, in a specific experimental model system, host genetic alterations may profoundly affect the composition of the intestinal microbiota and in fact lead to ‘reprogramming’ of the intestinal microbiota so that it could be inflammatory (ie, colitis-inducing) in its own right. Nod2−/− mice exhibit alterations in the composition of their ileal microbiota, characterised by an overall decreased load of commensal bacteria. However, a pathogenic role of these microbial alterations has not yet been reported (Nod2−/− mice do not develop intestinal inflammation). In human IBD, principal component analysis of 16S rRNA sequencing data of Crohn’s disease, patients with ulcerative colitis and healthy controls revealed a distinct common ‘IBD subset’ with decreased diversity and which represents ~1/3 Crohn’s disease and ~1/4 of patients with ulcerative colitis. At the—presumably—more relevant metagenomic level, IBD patients harboured 25% fewer genes in their microbiome compared to the control population. Principal component analysis of these metagenomic data revealed independent clustering into a healthy control cluster, a Crohn’s disease cluster and an ulcerative colitis cluster. Host genetic factors might not only alter the composition of the microbiota, the host may also respond improperly towards the microbiota. In the case of hypomorphic XBP1, NOD2 and ATG16L1 function, IECs and macrophages may become hypersensitive to the products of the bacteria making the process of bacterial mishandling self-replicating. The convergence of the main Crohn’s disease-associated genetic risk factors on autophagy could also suggest that the host might be particularly at risk for bacteria that gain access to the cytoplasm of cells such as Mycobacteria sp., Shigella sp., Salmonella sp. or AIEC. Thus, these risk genes could render the host particularly susceptible to enteropathogens or pathobionts that require normal autophagic function for their eradication.
Recent advances in basic science

Autophagy inducers and ER stress relievers may be potential novel treatment options in Crohn’s disease.

Neither show efficacy of everolimus, nor reproduce the well-established efficacy of azathioprine in this cohort of Crohn’s disease subjects. Given the latter, a meaningful interpretation of the data is precluded. Assuming that the intended mode of action of mTOR inhibitors might be different in Crohn’s disease (ie, induction of autophagy in IECs, macrophages, and DC) compared to organ transplantation (ie, T cell activation blockade and growth arrest), issues related to mTOR inhibitor dosing, as well as co-medications require specific scrutiny. For example, corticosteroids, which were used to induce remission in the everolimus trial, are well known to induce autophagic cell death, and hence corticosteroids could have precluded any potential benefit of everolimus. In summary, at this point the hypothesis that mTOR inhibitors might provide clinical benefit in Crohn’s disease cannot be rejected making additional controlled clinical trials warranted. Since IECs appear to play a particularly important role in the pathogenesis of IBD, Crohn’s disease and ulcerative colitis might even be amenable to local treatment modalities.

NEEDLESS TO SAY, mTOR is not only involved in controlling activation of autophagy, but also affects cell growth and proliferation, cellular metabolism, and other important biological pathways. Thus, pharmacological induction of autophagy via mTOR inhibition will have numerous additional effects that might or might not be beneficial in the context of Crohn’s disease. Autophagy could also be induced by a mTOR-independent route by lowering myo-inositol-1,4,5-triphosphate (IP3) levels and via further additional pathways. Notably, lithium, carbamazepin and sodium valproate act on inositol metabolism and lead to decreased levels of IP3.

Among those, carbamazepin has recently been shown to be highly effective in preventing disease via autophagy induction in an in vivo model of α1-antitrypsin (α1AT) deficiency, a disease characterised by hepatocellular aggregation of misfolded α1AT. A screen for pharmacological autophagy inducers that do not exert cellular toxicity revealed a further panel of eight autophagy inducers, of which seven represent FDA-approved drugs in use for various indications (fluspirilene, trifluoperazine, pimozone, rigudipine, nicardipine, amiodarone and loperamide). In vitro evidence further suggests that combinatorial treatment via mTOR-dependent as well as mTOR-independent induction of autophagy might have synergistic effects and therefore might offer advantages over treatment with maximum doses of single substances.

ER stress per se may similarly be amenable to pharmacological intervention. Chemical chaperones, like 4-phenyl butyric acid (PBA; an FDA-approved drug for urea-cycle disorders) and taurine-conjugated ursodeoxycholic acid (TUDCA) have been reported to reduce ER stress in vivo with consequent normalisation of insulin sensitivity in murine models of obesity and type 2 diabetes, conditions where increased ER stress plays a central role for impaired glucose homeostasis and inflammation. Interestingly, oral administration of TUDCA ameliorated inflammation in a rodent model of small intestinal inflammation.

Another convergent aspect of ATG16L1 and NOD2 function is the marked overproduction of IL-1ß from macrophages upon microbe-related stimulation. As discussed above, hypomorphic NOD2 or ATG16L1 function may lead to an IL-1ß-dependent increase in the severity of experimental colitis. Furthermore, an imbalance of IL-1ß expression relative to that of its antagonist (IL-1Ra) in the intestinal lamina propria of patients with Crohn’s disease, as well as efficacy of IL-1 receptor blockade in preclinical models as reported two decades ago are worthy of reconsideration. In addition, further preclinical data show that mice genetically deficient in the IL-1ß converting enzyme, caspase-1, are protected from experimental colitis. It is therefore remarkable that blockade of IL-1ß signalling, a quintessential inflammatory pathway, has not yet been adequately investigated in clinical trials in Crohn’s disease. It should also be noted that polymorphisms in NLRP3, a critical component of the inflammasome and hence IL-1ß

Key messages

- Intracellular sensing of bacteria and autophagy are regulated by NOD2.
- Intracellular bacteria are cleared via autophagy.
- Autophagy is a genetically determined (NOD2, ATG16L1 and IRGM), convergent mechanism in Crohn’s disease.
- Autophagy and endoplasmic reticulum stress are closely intertwined pathways.
- Autophagy inducers and ER stress relievers may be potential novel treatment options in Crohn’s disease.
activation and secretion, have been associated with Crohn’s disease.99 However, counter-intuitively, homozygosity for the NLRP3 risk allele was associated with decreased levels of IL-1β secretion from LPS-stimulated monocytes.99

CONCLUSIONS
The observations that genetic loci associated with autophagy (ATG16L1, IRGM and LRRK2), intracellular bacterial sensing (NOD2) and ER stress (XBp1 and ORMDL3) provide risk for the development of Crohn’s disease stresses the critical importance of microbial–host interactions in the pathogenesis of Crohn’s disease. These insights may also open up new potential considerations for therapy.

Funding Work in the authors’ laboratories is supported by the Austrian Science Fund (P21530 and START Y446 to A.K.), Innsbruck Medical University (grant 407 to A.K.), the European Research Council under the European Community’s Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement n 260961 (AK), the National Institutes of Health (RO1s DK088199, DK43419, DK53056 and DK51362 to R.S.B.) and the Harvard Digestive Diseases Center (DK034854 to RSB).

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES
Recent advances in basic science


Crohn's disease: NOD2, autophagy and ER stress converge

Teresa Fritz, Lukas Niederreiter, Timon Adolph, Richard S Blumberg and Arthur Kaser

Gut 2011 60: 1580-1588 originally published online January 19, 2011
doi: 10.1136/gut.2009.206466

Updated information and services can be found at:
http://gut.bmj.com/content/60/11/1580

These include:

References
This article cites 99 articles, 27 of which you can access for free at:
http://gut.bmj.com/content/60/11/1580#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (120)
Gut Education (56)
GUT Recent advances in basic science (86)
Crohn's disease (932)
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/